Gyroscope Therapeutics raises $148m in Forbion-led series C

The funding round also saw participation from Sofinnova Investments, T Rowe Price Associates, Tetragon Financial Group, an undisclosed healthcare-focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona, which injected $42.3m in financing.

Following the capital raise, Syncona now owns a 54% stake in the company, a press release by Syncona said.

Wouter Joustra, general partner at Forbion and Maha Katabi, general partner at Sofinnova, have been appointed to the Gyroscope board of directors.

Proceeds from the investment round will be used to advance GT005’s clinical development, as well as to advance its early stage pipeline and delivery technology.

Gyroscope Therapeutics had previously raised £50.4m in a series-B financing round from Syncona and Cambridge Innovation Capital in 2019.

Company
Founded in 2016 by Syncona and Cambridge Enterprise, Gyroscope is an ophthalmology company, developing genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company is based in Stevenage, with a further office in London and two bases in the US.

People
Forbion - Wouter Joustra (general partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Venture